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Abstract: Tick-borne encephalitis (TBE) virus is a major cause of central nervous system infections in
endemic countries. Here, we present clinical and laboratory characteristics of a large international
cohort of patients with confirmed TBE using a uniform clinical protocol. Patients were recruited in
eight centers from six European countries between 2010 and 2017. A detailed description of clinical
signs and symptoms was recorded. The obtained information enabled a reliable classification in 553 of
555 patients: 207 (37.3%) had meningitis, 273 (49.2%) meningoencephalitis, 15 (2.7%) meningomyelitis,
and 58 (10.5%) meningoencephalomyelitis; 41 (7.4%) patients had a peripheral paresis of extremities,
13 (2.3%) a central paresis of extremities, and 25 (4.5%) had single or multiple cranial nerve palsies.
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Five (0.9%) patients died during acute illness. Outcome at discharge was recorded in 298 patients.
Of 176 (59.1%) patients with incomplete recovery, 80 (27%) displayed persisting symptoms or signs
without recovery expectation. This study provides further evidence that TBE is a severe disease with
a large proportion of patients with incomplete recovery. We suggest monitoring TBE in endemic
European countries using a uniform protocol to record the full clinical spectrum of the disease.
Keywords: tick-borne encephalitis; vaccine-preventable disease; meningomyelitis; central paresis;
peripheral paresis
1. Introduction
Tick-borne encephalitis (TBE) is an infection of the central nervous system (CNS)
caused by the tick-borne encephalitis virus (TBEV) being transmitted by ticks in several
central, eastern, and northern European countries [1,2]. The severity of the disease is
broad, ranging from fever and headache to death, with a relatively high proportion of
patients needing intensive care unit (ICU) treatment. Most patients develop meningitis
or meningoencephalitis, some present with additional spinal involvement. At hospital
discharge, many patients suffer persisting signs like ataxia and tremor; symptoms such
as headache or decreased concentration are also described [3–5]. In addition, follow-up
studies have shown that 16–50% of patients suffer from long-lasting sequelae [6–11]. Since
the 1970s, a highly effective vaccine against TBE has been available and has led to a
significant decrease in cases in countries with high vaccination rates [12]. Nevertheless,
TBE remains an important issue caused by climate change and residual low vaccination
rates in several endemic countries [13,14]. Therefore, continuous monitoring and detailed
clinical analysis are needed to inform health care professionals and public authorities.
To the best of our knowledge, hitherto, only national or single-center studies describing
clinical details of TBE have been published. Here, we present a detailed description of
clinical characteristics of a large international cohort of patients fulfilling the European
Centre for Disease Prevention and Control (ECDC) case definition for confirmed TBE by
using a common clinical protocol.
2. Materials and Methods
2.1. Establishment of a Uniform Case Record Form (CRF) and Patient Recruitment
In 2013, the international network “European genetics study of tick-borne encephalitis”
(EU-TICK-BO) was established to investigate host genetic associations with the suscepti-
bility and severity of TBE. To provide a consistent description of TBE patients across all
centers, a uniform patient case record form (CRF) was established (Supplementary CRF).
Paper CRFs were filled out by the treating clinicians and entered into an electronic database.
In participating centers (Table S1), patients were prospectively collected between January
2014 and December 2017. A retrospective cohort was collected, starting from January 2010.
We used the ECDC case definition for TBE [1]. Clinical criteria included any person with
symptoms or signs of inflammation of the CNS (e.g., meningitis, meningoencephalitis,
meningoencephalomyelitis). Laboratory criteria included at least one of the following:
specific IgM and IgG antibodies in blood; specific IgM antibodies in cerebrospinal fluid
(CSF); seroconversion or four-fold increase of TBE-specific IgG antibodies in paired serum
samples. We included only patients with confirmed TBE, meeting the clinical and labo-
ratory criteria. Patients with a history of TBE vaccination were enrolled if infection with
TBEV was demonstrated either by an increase of TBEV IgG antibodies in convalescent
serum, by demonstration of TBEV-IgM in CSF, or by proof of a positive TBE-specific IgG
antibody CSF/serum index [15].
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2.2. Quality Control
Data integrity and plausibility were reviewed by two clinicians from the lead study
center. A list of missing items and unclear issues was sent out to each participating center.
If the centers were not able to provide a complete basic dataset (age, gender, admission
date, reliable laboratory evidence of a recent TBEV infection, and symptoms/signs in acute
stage), their patients were excluded.
2.3. Patient Assessment
The findings of each patient in the neurological phase were reviewed, and the follow-
ing diagnoses were assigned (modified according to Günther et al. 1997) [16]: meningitis,
moderate meningoencephalitis, severe meningoencephalitis, meningomyelitis, meningoen-
cephalomyelitis with moderate encephalitis, and meningoencephalomyelitis with severe
encephalitis. The following signs indicated moderate encephalitis: Glasgow Coma Score
(GCS) ≥ 9, ataxia, tremor, dysphagia, or single cranial nerve palsy. Severe encephalitis was
characterized by GCS < 9, seizures, central paresis, mechanical ventilation, multiple cranial
nerve palsies, or bulbar symptoms.
Pareses of extremities were categorized as peripheral paresis (a patient with flaccid
paresis of an extremity/extremities without signs of corresponding lesions in brain imag-
ing, if available) or central paresis (a patient with a spastic paresis of extremities, with
signs of corresponding lesions in brain imaging, if available). At discharge from hospital,
patients were categorized into “complete recovery” if symptoms or signs of TBE completely
vanished or “incomplete recovery at discharge” when TBE symptoms or signs were still
present. Patients with “incomplete recovery at discharge” were further categorized into
“complete recovery expected” and “incomplete recovery expected” based on the assess-
ment of the treating physician. Persisting symptoms or signs at discharge were categorized
into “mild subjective” if patients had one or two subjective symptoms, “severe subjective”
with three or more subjective symptoms, and “objective” if at least one objective sign with
or without subjective symptoms was observed. The main foci of this work were “findings
in acute disease”, “outcome at discharge”, and “blood and CSF findings”. Only “findings
in acute disease” were recorded in all included patients.
2.4. Statistical Analysis
Differences in patient characteristics in acute disease and outcome at discharge were
analyzed with the Kruskal–Wallis test with Dunn’s multiple comparisons test for continu-
ous variables and Fisher’s exact or Pearson’s chi-squared test for categorical variables. The
Kruskal–Wallis test, with Dunn’s multiple comparisons test, was performed to examine
the differences in blood and CSF levels according to diagnostic groups. For binary data,
p-values (p), together with odds ratios (OR) and their confidence intervals (CI), were re-
ported. Statistical analyses were conducted in R version 3.6.0 (R Foundation for Statistical
Computing, Vienna, Austria) and GraphPad Prism software version 8 (GraphPad Software,
La Jolla, CA, USA).
2.5. Literature Review
To set our findings in context with previously published TBE cohort descriptions, a
literature search was conducted on PubMed using the search term “(tick borne encephalitis
[Title/Abstract])”. Titles were screened for cohort descriptions using original patient data.
Information about frequency of diagnosis (meningitis, meningoencephalitis, meningoen-
cephalomyelitis, meningomyelitis), paresis, and fatality rates were extracted from full
articles from selected abstracts. We included original articles published between 1975 and
2020, with cohort sizes of at least 20 TBE patients presumably infected by the European
subtype of TBEV.
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2.6. Ethical Statement
The study was approved by the local ethics committee of each center, and appropriate
informed consent was obtained from all participating patients.
3. Results
3.1. Patient Characteristics and Findings in Acute Disease
A total of 1045 patients with TBE were recruited for genetic investigations (EU-TICK-
BO); 430 of a single center were excluded as they only participated in the genetic analysis;
17 patients were excluded due to their date of admission before 2010 and 43 because of
an incomplete basic data set after quality control. Finally, 555 (420 prospectively and
135 retrospectively recruited) cases were eligible for clinical description (Table 1), with
ages ranging from 11 months to 88 years (median of 50 years, interquartile range (IQR)
36–61). Overall, 23 patients were younger than 15 years; 144 (25.9%) patients had comor-
bidities or conditions: 95 (17.1%) had a cardiovascular disease, 17 (3.1%) had a pre-existing
neurological disease, 11 (1.9%) had a respiratory disease, 10 (1.8%) had a hematological
disease, and 8 (1.4%) had other comorbidities (5 patients with renal disease, 2 patients
with immunodeficiency and 1 patient with immunosuppression treatment after organ
transplant). Three (0.5%) patients were pregnant.
Table 1. Details of TBE patients, including basic characteristics, course of disease, severity of acute
disease, paresis and spinal involvement, and outcome at discharge.
Basic Characteristics All Patients (n = 555)
gender, female (%) 223 (40)
age, years (range) 50 (0–88)
BMI in adults, median (IQR) 26 (23–29) *
comorbidity (%) 144 (26)
TBE vaccination–any (%) 16 (2.9) *
tick bite noticed (%) 273 (61) *
transmission by dairy products (%) 11 (2)
course of disease
biphasic course (%) 329 (65) *
hospital stay (days), median (IQR) 10 (8–13) *
ICU admission (%) 38 (7) *
ICU length of stay median, days (IQR) 5 (2–8) *
diagnosis
meningitis (%) 207 (37.3)
meningoencephalitis, moderate (%) 241 (43.4)
meningoencephalitis, severe (%) 32 (5.8)
meningomyelitis (%) 15 (2.7)
meningoencephalomyelitis, moderate encephalitis (%) 46 (8.3)
meningoencephalomyelitis, severe encephalitis (%) 13 (2.3)
unknown (%) 2 (0.2)
neurological deficiencies
peripheral paresis (%) 41 (7.4)
central paresis (%) 13 (2.3)
unknown peripheral or central paresis (%) 2 (0.2)
single cranial palsy (%) 19 (3.4)
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Table 1. Cont.
Basic Characteristics All Patients (n = 555)
multiple cranial palsies (%) 6 (1.1)
disturbance of sensibility (%) 20 (5) *
bladder dysfunction (%) 20 (5) *
pain in extremities (%) 17 (4) *
respiratory paresis (%) 9 (2) *
rectal dysfunction (%) 9 (2) *
outcome at hospital discharge
complete recovery (%) 117 (39) *
incomplete recovery (%) 176 (59) *
death (%) 5 (2)
* Number of available observations: all patients: n = 555, except BMI (n = 315), TBE vaccination status (n = 546),
tick bite noticed (n = 444), course of illness (n = 504), length of hospital stay (n = 316), ICU admission (n = 554),
length of ICU stay (n = 34), respiratory paresis (n = 419), bladder dysfunction (n = 420), rectal dysfunction (n = 419),
disturbance of sensibility (n = 418), pain in extremities (n = 414), and outcome at hospital discharge (n = 298).
Sixteen (2.9%) patients had TBE despite being vaccinated. Out of these, seven were
vaccinated as recommended, six had no complete basic vaccination, and three had their last
booster vaccination not according to the recommendation. Most patients had a biphasic
course of disease (65.1%), with various symptoms or signs, including fever, fatigue, malaise,
headache, body pain, pharyngitis, and gastrointestinal symptoms (Table 1).
A clinical diagnosis was assigned to 553 of 555 patients; 207 (37.3%) had meningitis
(M), 241 (43.4%) moderate meningoencephalitis (ME mod.), 32 (5.8%) severe meningoen-
cephalitis (ME sev.), 15 (2.7%) meningomyelitis (MM), 46 (8.3%) meningoencephalomyelitis
(MEM) with moderate encephalitis, and 13 (2.3%) meningoencephalomyelitis with severe
encephalitis. In two patients, a differentiation of peripheral from central paresis was not
possible, and these patients were classified as “unknown”. The distribution of diagnoses
according to age is shown in Figure 1.
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Figure 1. Distribution of clinical diagnosis according to age groups.
3.2. Patients with Pareses at Acute Phase of Disease
In total, 56 (10.1%) patients had pareses of extremities, of whom 41 (7.4%) had periph-
eral pareses of extremities, 13 (2.3%) central pareses of extremities, and 2 had unknown
peripheral or central pareses of extremities (Table 2). A detailed distribution of pareses
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of extremities is shown in Table 2. Twenty-five (4.5%) patients had cranial nerve palsy.
Nineteen of them had a single cranial nerve palsy, and six had multiple cranial nerve
palsies. Further details about cranial nerve palsies were not recorded.
Table 2. Findings in patients with TBE in the initial phase and in the neurological phase.
Initial Phase n (%)





body pain 134 (27)
pharyngitis 70 (14)




nausea or vomiting 323 (61)
nuchal rigidity 396 (74)
positive Kernig sign 208 (40)
disturbance of consciousness 134 (24)
ataxia 206 (37)
tremor 210 (38)
single cranial nerve palsy 20 (4)
dysphagia 9 (2)
severe CNS dysfunction (GCS < 9) 13 (2)
seizures 8 (1)
central paresis 10 (2)
respiratory failure (in need of mechanical ventilation) 7 (1)
multiple cranial nerve palsies 6 (1)
bulbar palsy 15 (3)
CNS = central nervous system; GCS = Glasgow Coma Score. Number of available observations: in initial phase:
initial phase recorded (n = 505), including fever (n = 328), fatigue (n = 326), malaise (n = 327), headache (n = 329),
body pain (n = 327), pharyngitis (n = 326), gastrointestinal symptoms (327); findings in neurological phase: fever
(n = 535), headache (n = 534), nausea or vomiting (n = 530), nucheal rigidity (n = 532), positive Kernig’s sign
(n = 521), disturbance of consciousness, ataxia, tremor, single cranial nerve palsy and dysphagia (n = 553), severe
CNS dysfunction (n = 552), seizure (n = 554), central paresis (n = 553), respiratory failure (n = 553), multiple cranial
nerve palsies (n = 552), and bulbar palsy (n = 552).
3.3. Spinal Involvement
Spinal involvement was observed, including paresis of extremities (as reported),
disturbance of sensibility (n = 20), bladder dysfunction (n = 20), pain in extremities (n = 17),
respiratory paresis (n = 9), and rectal dysfunction (n = 9).
3.4. Correlation of Clinical Diagnosis
The following characteristics and findings were significantly associated with clinical
diagnosis: patients with M were younger than patients with ME (p < 0.0001), and pa-
tients with MEM (p = 0.002) had lower rates of comorbidities (OR = 0.52, p = 0.004 and
OR = 0.46, p = 0.03, respectively) and were less often admitted to the intensive care unit
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(ICU) (OR = 0.07, p < 0.0001 and OR = 0.10, p = 0.006, respectively) (Table 3). At discharge,
patients with M had higher rates of complete recovery than patients with ME (OR = 2.64,
p = 0.0006) and patients with MEM (OR = 13, p < 0.0001). Further, patients with ME had
higher rates of recovery compared to patients with MEM (OR = 2.6, p = 0.0006) (Table 3).
Accordingly, patients with M had lower rates of incomplete recovery than patients with
ME (OR = 0.38, p = 0.0006) and patients with MEM (OR = 0.07, p < 0.0001) (Table 3). Further
patient characteristics, including gender, body mass index (BMI), and vaccination status,
were not associated with specific clinical diagnoses.













gender female (%) 77 (37) 124 (45) 4 (27) 18 (31) p = 0.074
age median (IQR) 44 (29–57) 53 (41–63) 45 (30–64) 54 (44–63) p < 0.0001 *
BMI in adults, median
(IQR) 25 (23–29) 26 (23–28) 24 (22–27) 26 (24–30) p = 0.52
comorbidity (%) 38 (18) 82 (30) 5 (33) 19 (33) p = 0.011 *
TBE vaccination, any
(yes/no) 4 / 203 9/260 1 / 13 2 / 55 p = 0.40
tick bite noticed
(yes/no) 98 / 55 138/95 9 / 1 29 / 20 p = 0.21
transmission by dairy
products (%) 6 (3) 4 (1) 0 1 (2) n.a.
course of disease
biphasic course
(yes/no) 116 / 69 168 / 81 9 / 5 36 / 20 p = 0.77
hospital stay median
(IQR) 9 (8–11), n = 85 10 (8–13), n = 187 12 (10–18), n = 6 11 (9–17), n = 38 p = 0.013 *
ICU admission (%) 2 (1) 30 (11) 1 (7) 5 (9) p < 0.0001 *
ICU length of stay
median, days (IQR) 3 5 (2–7) n.a. 4 (2–12) p = 0.35
outcome at discharge from hospital
complete recovery (%) 50 (60) 60 (36) 3 (43) 4 (10) p < 0.0001 *
incomplete recovery
(%) 33 (40) 104 (62) 4 (57) 35 (88) p < 0.0001 *
death (%) 0 4 (2) 0 1 (3) p = 0.28
Abbreviations: n.a., not applicable. * Details on significance: age median: M vs. ME (p < 0.0001) and M vs. MEM (p = 0.002); comorbidity:
M vs ME (OR = 0.52, CI = 0.32–0.82; p = 0.004); M vs. MEM (OR = 0.46, CI = 0.23–0.94; p = 0.03,); hospital stay: M vs. MEM (p = 0.023); ICU
admission: M vs. ME (OR = 0.07, CI = 0.009–0.31; p < 0.0001) and M vs. MEM (OR = 0.10, CI = 0.01–0.7; p = 0.006); complete recovery at
hospital discharge: M vs. ME (OR = 2.64, CI = 1.5–4.7; p = 0.0006); M vs. MEM (OR = 13, CI = 4.1–55; p < 0.0001); ME vs. MEM (OR = 2.6,
CI = 1.5–4.7; p = 0.0006); incomplete recovery at hospital discharge: M vs. ME (OR = 0.38, CI = 0.21–0.68; p = 0.0006,); M vs. MEM (OR = 0.07,
CI = 0.02–0.24; p < 0.0001).
3.5. Outcome at Discharge
We recorded the outcome at the discharge of 298 patients; 117 (39%) had a complete
recovery, 176 (59%) an incomplete recovery, and 5 (2%) died. Based on the treating physi-
cian’s assessment, 96 (32%) patients were discharged with “complete recovery expected”,
while 80 (27%) were discharged with “no recovery expected” (Table 4).
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Table 4. Comparison of patients with complete recovery, incomplete recovery, and death.
Basic Characteristics Complete Recovery(n = 117)
Incomplete Recovery
(n = 176) Death (n = 5) Significance
female (%) 48 (41) 80 (45) 2 (40) p = 0.74
median age in years (IQR) 50 (28–64) 51 (40–61) 48 (43–73) p = 0.46
comorbidity (%) 36 (31) 54 (31) 4 (80) p = 0.076
TBE vaccination (%) 8 (7) 7 (4) 0 p = 0.45
tick bite noticed (%) 77 (66) 103 (59) 3 (60) p = 0.42
diary product (%) 2 (2) 5 (3) 0 p = 0.73
course of Disease
biphasic course 81 (70) 114 (65) 3 (60) p = 0.63
median BMI (IQR) 26 (23–29) 26 (24–29) 28 (22–35) p = 0.95
median hospital stay in days (IQR) 10 (8–12) 10 (8–14) 10 (9–11) p = 0.12
ICU admission (%) 8 (7) 20 (11) 4 (80) p = 0.0003 *
median days on ICU (IQR) 5 (3–5) 4 (2–7) 10 (9–11) p = 0.18
diagnosis
meningitis (%) 50 (42) 33 (19) 0 p < 0.0001 *
meningoencephalitis (%) 60 (51) 104 (59) 4 (80) p = 0.26
meningomyelitis (%) 3 (3) 4 (2) 0 p > 0.99
meningoencephalomyelitis (%) 4 (4) 35 (20) 1 (20) p < 0.0001 *
pareses
central paresis (%) 0 9 (5) 1 (20) p = 0.0036 *
peripheral paresis (%) 1 (2) 25 (14) 1 (20) p < 0.0001 *
cranial nerve palsy (%) 2 (2) 15 (9) 0 p = 0.049 *
spinal involvement
respiratory paresis (%) 1 (1) 7 (4) 0 p = 0.26
bladder dysfunction (%) 4 (3) 13 (7) 0 p = 0.40
rectal dysfunction (%) 1 (1) 6 (3) 0 p = 0.33
disturbance of sensibility 1 (1) 6 (3) 1 (20) p = 0.06
pain in extremities 1 (1) 16 (9) 0 p = 0.006 *
* Details about significance: ICU admission: death vs complete rec. (OR = 49.9, CI = 4.3–2651; p = 0.0002); death vs incompl. rec.
(OR = 30, CI = 2.8–1530; p = 0.001); diagnosis meningitis: incomplete rec. vs complete rec. (OR = 0.3, CI = 0.17–0.54; p < 0.0001); diagnosis
meningoencephalomyelitis: incomplete rec. vs complete rec (OR= 7, CI = 2.4–28; p < 0.0001); central paresis: incomplete rec. vs complete rec
(OR = infinity, CI = 1.4-infinity; p = 0.012); death vs. complete rec. (OR = infinity, CI= 0.6-infinity, p = 0.041); peripheral paresis: incomplete
rec. vs complete rec. (OR= 19, CI = 3–792; p < 0.0001); cranial nerve palsy: incomplete rec. vs complete rec. (OR = 5.3, CI = 1.2–49; p = 0.02);
pain in extremities: incomplete rec. vs complete rec. (OR = 12, CI = 1.7–490, p = 0.002).
Symptoms and signs of 121 patients discharged with incomplete recovery were
recorded (Table 5); 36 (30%) had mild subjective symptoms, 28 (23%) had severe sub-
jective symptoms, and 57 (47%) had objective signs, of whom 25 (20.5%) had one objective
sign, 25 (20.5%) had two objective signs, and 7 (6%) had three or more objective signs.
Headache (93% of patients) was a predominant subjective symptom, followed by decreased
concentration (47%). Objective signs included tremor (31%), ataxia (22%), and pareses of
extremities (16%) (Table 5).
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Table 5. Symptoms and signs of TBE in patients discharged with incomplete recovery.
Patients (n = 121)
Subjective Symptoms n (%)
headache 112 (93)
decreased concentration 57 (47)
decreased stress tolerance 27 (22)
increased irritability 21 (17)
decreased memory 32 (26)
emotional instability 24 (20)






cranial nerve palsy—ocular 0
cranial nerve palsy—facial 3 (2)




paresis of extremities 19 (16)
disturbance of sensibility 4 (3)
bladder dysfunction 1 (1)
bowel dysfunction 0
sexual dysfunction 0
3.6. Correlation of Outcome at Discharge
While there was no significant difference in ICU admission between patients with
complete and incomplete recovery (p = 0.227), deceased patients were admitted more often
to the ICU than patients with compete recovery (OR = 49.9, p = 0.0002) and patients with
incomplete recovery (OR = 30, p = 0.001). Further, deceased patients had higher rates of
central paresis than patients with complete recovery (OR = infinity, p = 0.041). Patients
with incomplete recovery were diagnosed less often with meningitis than patients with
complete recovery (OR = 0.3, p < 0.0001) and more often with meningoencephalomyelitis
(OR = 7, p < 0.0001), central paresis (OR = infinity, p = 0.012), peripheral paresis (OR = 19,
p < 0.0001), cranial palsy (OR = 5.3, p = 0.02), and pain in extremities (OR = 12, p = 0.002).
(Table 4).
3.7. Patients with Fatal Outcome
Patient 1 was a 39-year-old male with a kidney transplant and immunosuppression.
He developed a severe diffuse CNS dysfunction (GCS = 3), needed mechanical ventilation,
and died 4 weeks after the onset of TBE. The cause of death was described as extensive
brain inflammatory damage and destabilization of brain functions. Patient 2 was a 47-
year-old male with arterial hypertension and hyperuricemia. He had severe diffuse CNS
dysfunction (GCS = 3) and died from elevated intracranial pressure 4 weeks after the
onset of disease. Patient 3 was a 48-year-old female with arterial hypertension. She had
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severe diffuse CNS dysfunction (GCS = 3) and a central paresis. She died 4 weeks after the
onset of TBE. The cause of death was described as extensive brain inflammatory damage
and destabilization of brain functions. Patient 4 was a 66-year-old male with arterial
hypertension. He had a disturbance of sensibility, a paresis of the left arm, and neck muscle
dysfunction. He died within 4 weeks of TBE onset, caused by respiratory insufficiency.
Patient 5 was a 79-year-old female with arterial hypertension who died after 4 weeks of
TBE onset. The cause of death was not recorded.
3.8. Blood and CSF Findings
No differences in blood parameters were observed when patients were grouped
according to diagnosis (Figure S1). In CSF, we observed significant differences in protein
concentration (M lower than ME, p < 0.001; M lower than MEM, p < 0.001) and lactate
concentration (M lower than MEM, p < 0.05; ME lower than MEM, p < 0.05). There were
no significant differences in leukocyte, neutrophil, and lymphocyte counts and glucose
concentration (Figure S2).
3.9. Literature Review
In total, 37 clinical studies published between 1975 and 2020 were included [3,4,6,7,
10,11,16–46] (Table 6). The distribution of diagnoses showed the frequency of M ranging
from 7 to 78%, ME from 13 to 84%, and MEM from 3 to 11%. In children, M ranged from
63 to 97%, ME from 1.5 to 37%, and MEM from 0 to 4%. Only one study reported on MM
(Table S3). The description of paresis showed a frequency of overall paresis ranging from
1.6 to 10%, overall paresis of extremities ranging from 0.7 to 15.1%, peripheral paresis of
extremities ranging from 0 to 10.6%, central paresis of extremities ranging from 0.9 to 2.9%,
and cranial nerve palsies ranging from 1 to 11.3% (Table S4). In total, 34 clinical studies,
with a total of 35,875 patients, reported on mortality rates ranging from 0 to 6.3%, with no
significant improvement over the decades. Children had significantly lower fatality rates,
ranging from 0 to 0.2% (Table S5).
Table 6. Summary of results from the literature review and our study.







. . . of extremities, all 0.7–15.1 10.1
. . . of extremities, peripheral 0–10.6 7.4
. . . of extremities, central 0.9–2.9 2.3
. . . cranial nerve palsies 1–11.3 4.5
mortality rate 0–6.3 0.9
4. Discussion
This is the first multicenter report on clinical findings of TBE patients from six highly
endemic European countries. We confirm the high rates of patients with encephalitic
disease caused by TBEV in European countries, as previously described by single-center
studies or national studies [3,4,16,20,34]. The analysis of patient characteristics confirmed
higher age as a risk factor for severe disease, as has been shown before [4,20,24]. Older
age groups had a higher risk for meningoencephalitis and meningoencephalomyelitis.
Further, pre-existing comorbidities were identified as risk factors for meningoencephali-
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tis and meningoencephalomyelitis. Similar to previous reports, we observed a rela-
tively high proportion of patients with moderate (43.4%) and severe meningoencephalitis
(5.8%) [34,39,47]. Additionally, a high proportion of patients with myelitis (13.1%) was
seen, whereas 2.7% had myelitis without signs of encephalitis. Interestingly, case reports
about MM have been published, but the literature review showed only one clinical study
describing MM as a separate clinical diagnosis, [18] suggesting a likely underreporting
of patients with MM. A significant proportion of patients (10.1%) developed paresis of
extremities, which was consistent with previous publications suggesting a rate from 0.7%
to 15.1% [7,22]. Upper extremities were predominantly affected, as shown before [8]. In-
terestingly, a differentiation between peripheral and central paresis was rarely described,
and paresis was often summarized as limb paresis. Cranial nerve palsies were seen in
25 (4.5%) patients, which was consistent with previous publications suggesting a rate of 1%
to 11.3% [7,22]. A fatal course of disease was seen in 5 (1%) patients. Previous reports show
similar death rates ranging from 0 to 1.44% (Table S5). In our study, patients with a fatal
course of disease were aged between 39 to 79 years. Although we observed severe cases,
none of the pediatric cases died. A relatively low mortality rate in children and adolescents
has been reported before [31,44,45]. According to our findings and to the findings of the lit-
erature review, no significant decrease in mortality rates during the last decades was found.
The analysis of routine laboratory blood parameters showed no significant differences.
However, patients with M had significantly lower CSF protein and lactate concentrations
compared to patients with ME or MEM. These findings are consistent with previous studies
that reported elevated CSF protein levels in patients with ME [48]. Another study found an
association of high CSF protein levels with elevated rates of sequelae [5]. CSF lactate levels
are generally reported to be within a normal range [48,49], while publications on patients
with MEM also describe elevated CSF lactate levels [50]. More than half of the patients
were discharged with incomplete recovery (176/298 patients, 59%). This included a high
proportion (80/298 patients, 27%) with no expectation of complete recovery at discharge
according to the clinician’s assessment. Previous publications also describe high num-
bers of patients with sequelae after TBE infection [6,8,10,51,52]. Most impressively, TBE
causes pareses of extremities in 10.1% of patients, with incomplete recovery of paresis at
discharge. This impairment is a major factor for loss of function and loss of life quality and
attributes to the high burden of TBE disease [53]. Follow-up studies showed persistence of
pareses in more than 50% of patients one month after discharge [5,54]. Another follow-up
study showed that only a few patients had a resolution of pareses within 2–7 years after
discharge [52]. Further findings at discharge included a broad range of subjective symp-
toms (headache, decreased concentration, decreased stress tolerance) and objective signs
(tremor and ataxia). A Slovenian study investigated the burden of TBE, which amounted
to 3.1 disability-adjusted life years (DALYs) per TBE case [53]. In summary, TBE causes
severe sequelae and quantifiable long-lasting limitations in daily life.
Our cohort included 16 patients with a history of previous TBE vaccination; 7 patients
were fully vaccinated while 9 were incompletely vaccinated or missed receiving a booster
vaccination according to recommendations. In contrast to previous studies, we observed a
high proportion of children and adolescents with vaccination breakthrough infections [55,56].
In total, 9 of 16 vaccine breakthroughs were reported in patients younger than 20 years
of age, and 7 of them were from a single center in Austria. This high proportion of
children and adolescents with vaccination breakthrough infections might be the result of a
special screening program of the Department of General Paediatrics, Medical University of
Graz, to improve diagnostics in children with encephalitis and raise awareness for TBE
breakthrough infections.
Literature about the severity of TBE breakthrough infection is inconsistent. Previous
case reports and case series studies have described a more severe course of disease in
patients with vaccination breakthrough infection, while a recent publication investigating
a large cohort in Germany did not substantiate this finding [57,58]. The analysis of our
cohort showed no significant difference in the distribution of diagnosis or in outcome at
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discharge when comparing vaccinated or unvaccinated patients; however, the number of
breakthrough cases was low.
Although this analysis was carried out conscientiously, there may be potential limi-
tations. According to viral epidemiological data, in all patients with TBE infections, the
European TBEV subtype was presumed, though a differentiation of European, Siberian,
and Far Eastern subtypes was not made due to non-feasibility in clinical routine. Possible
coinfections with borrelia were excluded at each individual center according to clinical
routine. Borrelia-specific diagnostic results were neither recorded nor reviewed by the lead
study center. In this study, the true incidence of sequelae of our patients remains unknown.
We only recorded the outcome at discharge since standardized follow-up investigations in
all patients are of limited feasibility in routine patient care. Further investigation, including
a detailed follow-up protocol, will be needed to study this subject. Further, the categoriza-
tion of patients with incomplete outcomes at discharge for expected recovery is subjective
to the corresponding investigator and is influenced by personal experience.
5. Conclusions
This is the first international multicenter study of patients with TBE from different
European countries. We observed high rates of patients with encephalitis and high rates of
patients with lasting signs and symptoms at discharge. The comparison with previously
published cohorts showed a likely underreporting of patients with meningomyelitis and
patients with central paresis, which might be caused by different case record forms. There-
fore, we suggest the use of a uniform case record form to monitor the full spectrum of
disease and to raise awareness for disease prevention, particularly in countries with low
vaccination rates.
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